Exploring Real-World HER2-Low Data in Early-Stage Triple-Negative Breast Cancer: Insights and Implications

References

• Smolarz B, Nowak AZ, Romanowicz H. Breast cancer-epidemiology, classification, pathogenesis and treatment (review of literature). Cancers. 2022;14(10):2569. doi:10.3390/cancers14102569
   PubMed Web of Science ®Google Scholar
• Hammond MEH, Hayes DF, Dowsett M, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med. 2010;134(7):e48–72. doi:10.1043/1543-2165-134.7.e48
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. JCO. 2018;36(20):2105–2122. doi:10.1200/JCO.2018.77.8738
   PubMed Web of Science ®Google Scholar
• Trivers KF, Lund MJ, Porter PL, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control. 2009;20(7):1071–1082. doi:10.1007/s10552-009-9331-1
   PubMed Web of Science ®Google Scholar
• Modi S, Jacot W, Yamashita T, et al. Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer. N Engl J Med. 2022;387(1):9–20. doi:10.1056/NEJMoa2203690
   PubMed Web of Science ®Google Scholar
• Nguyen X, Hooper M, Borlagdan JP, Palumbo A. A review of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer. Ann Pharmacother. 2021;55(11):1410–1418. doi:10.1177/1060028021998320
   PubMed Web of Science ®Google Scholar
• Koster KL, Huober J, Joerger M. New antibody-drug conjugates (ADCs) in breast cancer—an overview of ADCs recently approved and in later stages of development. Explor Target Antitumor Ther. 2022;3(1):27–36. doi:10.37349/etat.2022.00069
   PubMedGoogle Scholar
• Li Y, Abudureheiyimu N, Mo H, et al. In real life, low-level HER2 expression may be associated with better outcome in HER2-negative breast cancer: a study of the national cancer center, China. Front Oncol. 2021;11:774577. doi:10.3389/fonc.2021.774577
   PubMed Web of Science ®Google Scholar
• Gampenrieder SP, Rinnerthaler G, Tinchon C, et al. Landscape of HER2-low metastatic breast cancer (MBC): results from the Austrian AGMT_MBC-Registry. Breast Cancer Res. 2021;23(1):112. doi:10.1186/s13058-021-01492-x
   PubMed Web of Science ®Google Scholar
• Chiu AM, Mitra M, Boymoushakian L, Coller HA. Integrative analysis of the inter-tumoral heterogeneity of triple-negative breast cancer. Sci Rep. 2018;8(1):11807. doi:10.1038/s41598-018-29992-5
   PubMed Web of Science ®Google Scholar
• Denkert C, Seither F, Schneeweiss A, et al. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials. Lancet Oncol. 2021;22(8):1151–1161. doi:10.1016/S1470-2045(21)00301-6
   PubMed Web of Science ®Google Scholar
• Agostinetto E, Rediti M, Fimereli D, et al. HER2-low breast cancer: molecular characteristics and prognosis. Cancers. 2021;13(11):2824. doi:10.3390/cancers13112824
   PubMed Web of Science ®Google Scholar
• Schettini F, Chic N, Brasó-Maristany F, et al. Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. Npj Breast Cancer. 2021;7(1):1–13. doi:10.1038/s41523-020-00208-2
   PubMed Web of Science ®Google Scholar
• Wolff AC, Hammond MEH, Hicks DG, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013. doi:10.1200/JCO.2013.50.9984
   PubMed Web of Science ®Google Scholar
• Giuliano AE, Edge SB, Hortobagyi GN. Eighth Edition of the AJCC cancer staging manual: breast cancer. Ann Surg Oncol. 2018;25(7):1783–1785. doi:10.1245/s10434-018-6486-6
   PubMed Web of Science ®Google Scholar
• Irvin WJ, Carey LA. What is triple-negative breast cancer? Eur J Cancer. 2008;44(18):2799–2805. doi:10.1016/j.ejca.2008.09.034
   PubMed Web of Science ®Google Scholar
• IBGE. Pesquisa das Características Étnico—Raciais da População—PCERP [Research on the Ethnic-Racial Characteristics of the Population—Raciais da População—PCERP]; 2008. Available from: https://www.ibge.gov.br/estatisticas/sociais/populacao/9372-caracteristicasetnico-raciais-da-populacao.html?=&t=o-que-e. Accessed October 15, 2019.
   Google Scholar
• Nahleh Z, Sivasubramaniam D, Dhaliwal S, Sundarajan V, Komrokji R. Residual cancer burden in locally advanced breast cancer: a superior tool. Curr Oncol. 2008;15(6):271–278. doi:10.3747/co.v15i6.242
   PubMed Web of Science ®Google Scholar
• Hurvitz SA. DESTINY-changing results for advanced breast cancer. N Engl J Med. 2022;387(1):75–76. doi:10.1056/NEJMe2206661
   PubMed Web of Science ®Google Scholar
• Polónia A, Canelas C, Caramelo A. The spectrum of HER2 expression in breast cancer: linking immunohistochemistry quantification with in situ hybridization assay. Virchows Arch. 2022;480(6):1171–1179. doi:10.1007/s00428-022-03290-y
   PubMed Web of Science ®Google Scholar
• Venetis K, Crimini E, Sajjadi E, et al. HER2 low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer. Front Mol Biosci. 2022;9. doi:10.3389/fmolb.2022.834651
   Web of Science ®Google Scholar
• Asleh K, Riaz N, Nielsen TO. Heterogeneity of triple negative breast cancer: current advances in subtyping and treatment implications. J Exp Clin Cancer Res. 2022;41(1):265. doi:10.1186/s13046-022-02476-1
   PubMed Web of Science ®Google Scholar
• da Silva JL, de Paula BHR, Small IA, Thuler LCS, de Melo AC. Sociodemographic, clinical, and pathological factors influencing outcomes in locally advanced triple negative breast cancer: a Brazilian Cohort. Breast Cancer (Auckl). 2020;14:1178223420962488. doi:10.1177/1178223420962488
   Web of Science ®Google Scholar
• Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429–4434. doi:10.1158/1078-0432.CCR-06-3045
   PubMed Web of Science ®Google Scholar
• Peintinger F, Sinn B, Hatzis C, et al. Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy. Mod Pathol. 2015;28(7):913–920. doi:10.1038/modpathol.2015.53
   PubMed Web of Science ®Google Scholar
• de Calbiac O, Lusque A, Mailliez A, et al. Comparison of management and outcomes in ERBB2-Low vs ERBB2-Zero metastatic breast cancer in France. JAMA Netw Open. 2022;5(9):e2231170. doi:10.1001/jamanetworkopen.2022.31170
   PubMed Web of Science ®Google Scholar
• Qaiser T, Mukherjee A, Reddy PC, et al. HER2 challenge contest: a detailed assessment of automated HER2 scoring algorithms in whole slide images of breast cancer tissues. Histopathology. 2018;72(2):227–238. doi:10.1111/his.13333
   PubMed Web of Science ®Google Scholar
• Farahmand S, Fernandez AI, Ahmed FS, et al. Deep learning trained on hematoxylin and eosin tumor region of Interest predicts HER2 status and trastuzumab treatment response in HER2+ breast cancer. Mod Pathol. 2022;35(1):44–51. doi:10.1038/s41379-021-00911-w
   PubMed Web of Science ®Google Scholar
• Gustavson M, Haneder S, Spitzmueller A, et al. Abstract PD6-01: novel approach to HER2 quantification: digital pathology coupled with AI-based image and data analysis delivers objective and quantitative HER2 expression analysis for enrichment of responders to trastuzumab deruxtecan (T-DXd; DS-8201), specifically in HER2-low patients. Cancer Res. 2021;81(4_Supplement):PD6–01. doi:10.1158/1538-7445.SABCS20-PD6-01
   Web of Science ®Google Scholar
• Businesswire. Paige answers call to better identify breast cancer patients with low expression of HER2; 2022. Available from: https://www.businesswire.com/news/home/20220623005253/en/Paige-Answers-Call-to-Better-Identify-Breast-Cancer-Patients-with-Low-Expression-of-HER2. Accessed February 5, 2023.
   Google Scholar
• Moutafi M, Robbins CJ, Yaghoobi V, et al. Quantitative measurement of HER2 expression to subclassify ERBB2 unamplified breast cancer. Lab Invest. 2022;102(10):1101–1108. doi:10.1038/s41374-022-00804-9
   PubMed Web of Science ®Google Scholar
• Kennedy JJ, Whiteaker JR, Kennedy LC, et al. Quantification of human epidermal growth factor receptor 2 by immunopeptide enrichment and targeted mass spectrometry in formalin-fixed paraffin-embedded and frozen breast cancer tissues. Clin Chem. 2021;67(7):1008–1018. doi:10.1093/clinchem/hvab047
   PubMed Web of Science ®Google Scholar
• Xu K, Bayani J, Mallon E, et al. Discordance between Immunohistochemistry and Erb-B2 Receptor Tyrosine Kinase 2 mRNA to determine human epidermal growth factor receptor 2 low status for breast cancer. J Mol Diagn. 2022;24(7):775–783. doi:10.1016/j.jmoldx.2022.04.002
   PubMed Web of Science ®Google Scholar